Table of Contents
Volume 1 | Issue 2
Publication Date: November 1999- Abstract
- No Access
- Pay-Per View
- Full Text
- Add to Cart
Researches in Brief | ||
90-91 |
1999 European Cancer Conference CIG Media Group |
|
92-93 |
Randomized Phase III Comparing Docetaxel to Best Supportive Care for Previously Untreated Advanced NSCLC1 CIG Media Group |
|
94-95 |
Randomized Phase III Trial Comparing Cisplatin/Gemcitabine/Vinorelbine to Cisplatin/Gemcitabine or Cisplatin/Vinorelbine in Patients with Advanced NSCLC1 CIG Media Group |
|
Comprehensive Review | ||
100-106 |
Lung Cancer Screening in High-Risk Populations Jill M. Siegfried |
|
Commentary | ||
107 |
Commentary on “Lung Cancer Screening in High-Risk Populations” James L. Mulshine |
|
Comprehensive Review | ||
110-117 |
The Benefits of Support Group Participation to Lung Cancer Survivors — An Evaluation Margaret M. McCarthy, Anne Thompson, Scott Rivers, Mohammad Jahanzeb |
|
Commentaries | ||
118 |
Commentary on “The Benefits of Support Group Participation to Lung Cancer Survivors” William K. Evans |
|
119 |
Commentary on “The Benefits of Support Group Participation to Lung Cancer Survivors” Harvey I. Pass |
|
Comprehensive Review | ||
122-127 |
Sequential Chemotherapy: Rationale and Clinical Trial Design in Advanced Non–Small-Cell Carcinoma Martin J. Edelman, David R. Gandara |
|
Commentaries | ||
128 |
Commentary on “Sequential Chemotherapy: Rationale and Clinical Trial Design in Advanced Non–Small-Cell Carcinoma” John R. Eckardt |
|
129 |
Commentary on “Sequential Chemotherapy: Rationale and Clinical Trial Design in Advanced Non–Small-Cell Carcinoma” Vassilis Georgoulias |
|
Imaging in Lung Cancer | ||
130-136 |
Lung Cancer: Value of Various Imaging Modalities Robert Rivera-Garcia, Charles S. White, Philip A. Templeton |
|
Commentary | ||
137 |
Commentary on “Lung Cancer: Value of Various Imaging Modalities” Naresh C. Gupta |
|
Translational Medicine | ||
138-143 |
The Anti-Apoptosis Survivin Gene and its Role in Human Cancer: An Overview Daniel Escuín, Rafael Rosell |
|
Original Contribution | ||
144-150 |
Docetaxel and Cisplatin in Patients with Advanced Non–Small-Cell Lung Cancer (NSCLC): A Multicenter Phase II Trial Chandra P. Belani, Philip Bonomi, Tracey W. Dobbs, Russell F. DeVore, David S. Ettinger, James Jett, James D. Luketich, Lewis J. Cohen, David H. Johnson |
|
Current Trials | ||
151-152 |
Phase I Study of Bryostatin-1 in Combination with Cisplatin in Treating Patients with Metastatic or Unresectable Solid Tumors Including Non–Small-Cell Lung Cancer Heinz-Josef Lenz, Derek Raghavan, James Doroshow, David R. Gandara |
|
153-154 |
Twice-Weekly Gemcitabine and Concurrent Thoracic Radiation for Advanced Non–Small-Cell Lung Cancer A. William Blackstock, Frederick Richards, Douglas White, Glenn Lesser |
|